Selected Impact

Commercial impact, measured.

Selected evidence of portfolio scale, recurring-revenue growth, market expansion, launch performance, and stronger teams.

Business context and scale

$500M

Global services portfolio

Led global marketing for a services portfolio that grew from $300M to $500M across nine life sciences business units.

Life sciences business units

Supported cross-divisional commercialization across distinct customer workflows, service models, and commercial teams.

Direct commercial outcomes

25% → 28%

Service capture rate

Improved service capture across a global installed base.

~$18M

Incremental recurring revenue

Associated with the three-point improvement in service capture.

$10M

Qualified pipeline

Generated through enriched customer data, sharper segmentation, and more focused targeting.

Market and launch outcomes

+322%

Structural biology segment growth

Activated an underserved opportunity through customer insight, positioning, and sales enablement.

+40%

ExpiCHO launch performance

Above first-year forecast; recognized with the Life Sciences Innovation Award.

+350%

Lipofectamine 3000 launch performance

Above first-year forecast; recognized with two Marketing Excellence Awards.

$60M → $115M

Portfolio growth

Growth across a mammalian transient protein expression technology portfolio.

7 → 15

Global marketing team scaled

Expanded leadership depth, strategic capability, planning discipline, and commercial influence.

The numbers show the outcomes. The case studies reveal the choices, alignment, and execution behind them.

For leadership opportunities, commercial challenges, and strategic growth conversations.

Resumes